# Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects

> **NCT05806177** · PHASE1 · COMPLETED · sponsor: **South China Center For Innovative Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** AD16 30mg、40mg
- **DRUG:** AD16 Placebo 30mg、40mg

## Key facts

- **NCT ID:** NCT05806177
- **Lead sponsor:** South China Center For Innovative Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-26
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806177, "Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05806177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*